Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease

키워드

참고문헌 (73)

1. Sakane T, "Behçet’s disease", N Engl J Med, 341, pp.1284~1291 (1999)
2. James DG, "Behcet’s syndrome", N Engl J Med, 301, pp.431~432 (1979)
3. Nakata K, "Neuro-Behçet’s syndrome: report of an autopsy case", Bull Osaka Med Sch, 10, pp.105~119 (1964)
4. Cheon JH, "An update on the diagnosis, treatment, and prognosis of intestinal Behçet’s disease", Curr Opin Rheumatol, 27, pp.24~31 (2015)
5. Lee CR, "Colonoscopic findings in intestinal Behçet’s disease", Inflamm Bowel Dis, 7, pp.243~249 (2001)
6. Park J, "Risk factors and outcomes of acute lower gastrointestinal bleeding in intestinal Behçet’s disease", Int J Colorectal Dis, 32, pp.745~751 (2017)
7. Jung YS, "Clinical course of intestinal Behcet’s disease during the first five years", Dig Dis Sci, 58, pp.496~503 (2013)
8. Han M, "Incidence and clinical outcomes of intestinal Behçet’s disease in Korea, 2011-2014: a nationwide population-based study", J Gastroenterol, 52, pp.920~928 (2017)
9. Lopalco G, "Update on the medical management of gastrointestinal Behçet’s disease", Mediators Inflamm, 2017, pp.1460491~ (2017)
10. Tadakazu Hisamatsu, "Treatment and outcomes: medical and surgical treatment for intestinal Behçet’s disease", Intestinal research, 15(3), pp.318~327 (2017), 대한장연구학회
11. Hisamatsu T, "The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet’s disease: indication of anti-TNFalpha monoclonal antibodies", J Gastroenterol, 49, pp.156~162 (2014)
12. Goel N, "Certolizumab pegol", MAbs, 2, pp.137~147 (2010)
13. Nanke Y, "The role of Th17 cells in the pathogenesis of Behcet’s disease", J Clin Med, 6, pp.E74~ (2017)
14. Frassanito MA, "Th1 polarization of the immune response in Behçet’s disease: a putative pathogenetic role of interleukin-12", Arthritis Rheum, 42, pp.1967~1974 (1999)
15. Gül A, "Behçet’s disease: an update on the pathogenesis", Clin Exp Rheumatol, 19(5 Suppl 24), pp.S6~S12 (2001)
16. Evereklioglu C, "Serum levels of TNFalpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet’s disease", Mediators Inflamm, 11, pp.87~93 (2002)
17. Emmi G, "Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Behcet patients and exhibit high levels of TNF-alpha in early phases of the disease", Medicine (Baltimore), 95, pp.e5516~ (2016)
18. Kappen JH, "Cytokines in the colon of a patient with Behçet’s disease", Arthritis Res Ther, 11, pp.412~ (2009)
19. Misumi M, "Cytokine production profile in patients with Behcet’s disease treated with infliximab", Cytokine, 24, pp.210~218 (2003)
20. Accardo-Palumbo A, "Phenotype and functional changes of Vgamma9", Vdelta2 T lymphocytes in Behçet’s disease and the effect of infliximab on Vgamma9, Arthritis Res Ther, pp.2010, 12[DOI]
21. Sugita S, "Induction of T regulatory cells by cytotoxic T-lymphocyte antigen-2alpha on corneal endothelial cells", Invest Ophthalmol Vis Sci, 52, pp.2598~2605 (2011)
22. Sugita S, "Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet’s disease", Arthritis Res Ther, 14, pp.R99~ (2012)
23. Hassard PV, "Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet’s disease: a case report", Gastroenterology, 120, pp.995~999 (2001)
24. Iwata S, "Efficacy of combination therapy of anti-TNF-alpha antibody infliximab and methotrexate in refractory entero-Behçet’s disease", Mod Rheumatol, 21, pp.184~191 (2011)
25. Lee JH, "Efficacy of infliximab in intestinal Behçet’s disease: a Korean multicenter retrospective study", Inflamm Bowel Dis, 19, pp.1833~1838 (2013)
26. Kinoshita H, "Efficacy of infliximab in patients with intestinal Behçet’s disease refractory to conventional medication", Intern Med, 52, pp.1855~1862 (2013)
27. Ideguchi H, "Gastrointestinal manifestations of Behçet’s disease in Japan: a study of 43 patients", Rheumatol Int, 34, pp.851~856 (2014)
28. Vallet H, "Efficacy of anti-TNF alpha in severe and", or refractory Behçet’s disease: multicenter study of 124 patients, 2015, pp.62, 67~74
29. Hibi T, "Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study", Medicine (Baltimore), 95, pp.e3863~ (2016)
30. Zou J, "Long-term outcomes and predictors of sustained response in patients with intestinal Behcet’s disease treated with infliximab", Dig Dis Sci, 62, pp.441~447 (2017)
31. Travis SP, "Treatment of intestinal Behçet’s syndrome with chimeric tumour necrosis factor alpha antibody", Gut, 49, pp.725~728 (2001)
32. Kram MT, "Behçet’s ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case", Dis Colon Rectum, 46, pp.118~121 (2003)
33. Jung Hoon Lee, "Remission of intestinal Beh？et's disease treated with anti-tumor necrosis factor α monoclonal antibody (Infliximab)", The Korean Journal of Internal Medicine, 22(1), pp.24~27 (2007), 대한내과학회
34. Byeon JS, "Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet’s disease: report of a case", Dis Colon Rectum, 50, pp.672~676 (2007)
35. Ugras M, "Infliximab as an alternative treatment for Behçet disease when other therapies fail", J Pediatr Gastroenterol Nutr, 46, pp.212~215 (2008)
36. Naganuma M, "Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet’s disease", Inflamm Bowel Dis, 14, pp.1259~1264 (2008)
37. Maruyama Y, "A case of intestinal Behçet’s disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years", Intern Med, 51, pp.2125~2129 (2012)
38. Cheon JH, "Development, validation, and responsiveness of a novel disease activity index for intestinal Behçet’s disease", Inflamm Bowel Dis, 17, pp.605~613 (2011)
39. 박지혜, "Could adalimumab be used safely and effectively in intestinal Behçet’s disease refractory to conventional therapy?", Intestinal research, 15(3), pp.263~265 (2017), 대한장연구학회
40. Cheon JH, "Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease", J Gastroenterol Hepatol, 32, pp.769~777 (2017)
41. Tanida S, "Adalimumab for the treatment of Japanese patients with intestinal Behçet’s disease", Clin Gastroenterol Hepatol, 13, pp.940~948.e3 (2015)
42. Tanida S, "Long-term efficacy of adalimumab in patients with intestinal Behcet’s disease: eight consecutive cases", J Clin Med Res, 8, pp.334~337 (2016)
43. Nagamu Inoue, "Long-term safety and efficacy of adalimumab for intestinal Behçet’s disease in the open label study following a phase 3 clinical trial", Intestinal research, 15(3), pp.395~401 (2017), 대한장연구학회
44. Vitale A, "Adalimumab effectiveness in Behçet’s disease: short and long-term data from a multicenter retrospective observational study", Clin Rheumatol, 36, pp.451~455 (2017)
45. van Laar JA, "Adalimumab: a new modality for Behçet’s disease", Ann Rheum Dis, 66, pp.565~566 (2007)
46. De Cassan C, "Successful treatment with adalimumab in a familial case of gastrointestinal Behcet’s disease", J Crohns Colitis, 5, pp.364~368 (2011)
47. Toyonaga T, "Refractoriness of intestinal Behçet’s disease with myelodysplastic syndrome involving trisomy 8 to medical therapies: our case experience and review of the literature", Digestion, 88, pp.217~221 (2013)
48. Masamichi Kimura, "Usefulness of Adalimumab for Treating a Case of Intestinal Behçet’s Disease With Trisomy 8 Myelodysplastic Syndrome", Intestinal research, 13(2), pp.166~169 (2015), 대한장연구학회
49. Mizoshita T, "Adalimumab treatment in intestinal Behçet’s disease: relationship with ectopic mucin 5AC glycoprotein expression and endoscopic improvement", Dig Liver Dis, 47, pp.991~992 (2015)
50. Smola MG, "Surgical treatment of dermatofibrosarcoma protuberans: a retrospective study of 20 cases with review of literature", Eur J Surg Oncol, 17, pp.447~453 (1991)
51. Ma D, "Etanercept in the treatment of intestinal Behcet’s disease", Cell Biochem Biophys, 69, pp.735~739 (2014)
52. Vitale A, "Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease", Clin Rheumatol, 36, pp.2063~2069 (2017)
53. Lopalco G, "Certolizumab pegol treatment in Behcet’s disease with different organ involvement: a multicenter retrospective observational study", Mod Rheumatol, 27, pp.1031~1035 (2017)
54. Watanabe S, "A young girl with refractory intestinal Behçet’s disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent", Rheumatol Int, 33, pp.3105~3108 (2013)
55. Melikoglu M, "Short-term trial of etanercept in Behçet’s disease: a double blind, placebo controlled study", J Rheumatol, 32, pp.98~105 (2005)
56. Curigliano V, "Efficacy of etanercept in the treatment of a patient with Behçet’s disease", Clin Rheumatol, 27, pp.933~936 (2008)
57. Mohammed RH, "Etanercept therapy in Behçet’s disease: the tight control strategy in refractory disease", Z Rheumatol, 73, pp.650~656 (2014)
58. Iriarte A, "Inflammatory bowel disease as a paradoxical effect of anti-TNF alpha therapy", Gastroenterol Hepatol, 40, pp.117~121 (2017)
59. Dallocchio A, "Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study", Rheumatology (Oxford), 49, pp.1694~1698 (2010)
60. Braun J, "Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents", Arthritis Rheum, 57, pp.639~647 (2007)
61. Hutas G, "Golimumab, a fully human monoclonal antibody against TNFalpha", Curr Opin Mol Ther, 10, pp.393~406 (2008)
62. Targownik LE, "Infectious and malignant complications of TNF inhibitor therapy in IBD", Am J Gastroenterol, 108, pp.1835~1842 (2013)
63. Bewtra M, "Lymphoma in inflammatory bowel disease and treatment decisions", Am J Gastroenterol, 107, pp.964~970 (2012)
64. Siegel CA, "Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis", Clin Gastroenterol Hepatol, 7, pp.874~881 (2009)
65. Long MD, "Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease", Clin Gastroenterol Hepatol, 8, pp.268~274 (2010)
66. Magro F, "Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III)", J Crohns Colitis, 8, pp.31~44 (2014)
67. Stübiger N, "Behçet’s disease. Epidemiology, clinical manifestations, immunology and therapy", Ophthalmologe, 109, pp.529~530 (2012)
68. Jung YS, "Cancer risk in the early stages of inflammatory bowel disease in Korean patients: a nationwide population-based study", J Crohns Colitis, 11, pp.954~962 (2017)
69. Hisamatsu T, "Diagnosis and management of intestinal Behçet’s disease", Clin J Gastroenterol, 7, pp.205~212 (2014)
70. Lichtenstein GR, "A pooled analysis of infections, malignancy, and mortality in infliximaband immunomodulator-treated adult patients with inflammatory bowel disease", Am J Gastroenterol, 107, pp.1051~1063 (2012)
71. Byun JM, "Risks for opportunistic tuberculosis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor necrosis factor-alpha inhibitor", Scand J Gastroenterol, 50, pp.312~320 (2015)
72. Huang ML, "Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: a retrospective study", J Crohns Colitis, 8, pp.282~287 (2014)
73. Jung YS, "Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet’s disease", Inflamm Bowel Dis, 18, pp.750~757 (2012)

관련 논문AI추천